Cardiac Pacemakers Market Report 2025

This Cardiac Pacemakers market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The cardiac pacemakers market size has grown strongly in recent years. It will grow from $4.73 billion in 2024 to $4.98 billion in 2025 at a compound annual growth rate (CAGR) of 5.3%. The growth in the historic period can be attributed to aging population and the prevalence of cardiovascular diseases, growing awareness of arrhythmias and the need for treatment, investment in research and development for pacemaker innovation, evolving healthcare infrastructure and access to medical devices, and regulatory approvals for novel pacemaker features and technologies.

The cardiac pacemakers market size is expected to see strong growth in the next few years. It will grow to $6.51 billion in 2029 at a compound annual growth rate (CAGR) of 6.9%. The growth in the forecast period can be attributed to focus on lead durability and reduction of complications, remote programming and telehealth services for pacemaker patients, expansion of emerging markets and rising healthcare expenditure, enhanced battery technologies for longer pacemaker lifespans, and regulatory support for expedited pacemaker approvals. Major trends in the forecast period include electrophysiology advancements for precision implantation, integration of pacemaker data into electronic health records (ehrs), integration of artificial intelligence (ai) for predictive pacemaker maintenance, advancements in pacemaker technology, including miniaturization, and telemedicine and remote monitoring.

The surge in cardiovascular diseases is a significant driver for the cardiac pacemaker market. Cardiovascular diseases encompass a range of disorders affecting the heart or blood vessels, including arrhythmias, aorta disease, congenital heart disease, and heart attacks. To address the growing global health concern, cardiac pacemakers, which generate electric activity, are employed in treating patients with cardiovascular diseases. In September 2023, the World Health Organization reported that annually, 41 million deaths, accounting for 74% of non-communicable diseases, were attributed to cardiovascular diseases, highlighting the pressing need for advancements in cardiac care. Consequently, the increasing prevalence of cardiovascular diseases is expected to propel the growth of the cardiac pacemaker market.

Government initiatives aimed at fostering research and development in healthcare are poised to drive the cardiac pacemaker market. These initiatives, undertaken by government authorities at various levels, encompass actions, programs, and policies designed to address healthcare challenges and promote positive societal changes. Notably, in 2022, the UK government allocated £260 million ($270.65 million) in funding to bolster healthcare research and manufacturing. This commitment, from the Department of Health and Social Care, supports NHS-led health research into diagnostics and treatments, with a focus on enhancing clinical research services. Additionally, £60 million ($63.6 million) was earmarked to expand life sciences manufacturing in the UK. Such government initiatives play a pivotal role in advancing cardiac care and fueling the growth of the cardiac pacemaker market.

Innovations, particularly the development of leadless cardiac pacemakers, emerge as a key trend in the cardiac pacemaker market. Major players in the industry are actively introducing innovative solutions to enhance patient care and market competitiveness. The leadless pacemaker, a self-contained generator and electrode system, offers significant advantages, being 90% smaller than traditional transvenous pacemakers. Its implantation via a femoral vein transcatheter technique eliminates the need for chest incisions and subcutaneous generator pockets. Notably, in January 2022, Medtronic PLC, an Ireland-based medical devices company, introduced the Micra AV Transcatheter Pacing System (TPS), a leadless pacemaker designed for patients with compromised electrical communication between the heart's ventricle and atria, addressing a critical aspect of cardiac health with cutting-edge technology.

Major companies in the cardiac pacemaker market are innovating products such as i2i communication technology, which facilitates real-time communication between two devices. This i2i (infrastructure-to-infrastructure) communication technology allows seamless data exchange between different infrastructure systems, enhancing automation and operational efficiency. For example, in November 2023, Abbott Laboratories, a US-based medical device company, launched the AVEIR DR System to treat patients with abnormal or slow heart rhythms. This cutting-edge dual-chamber leadless pacemaker system provides synchronized pacing for both the right atrium and ventricle, ensuring a proper heart rhythm. It is implanted using a minimally invasive procedure, which decreases recovery time and complications. The advanced implant-to-implant technology enables real-time communication between the devices, coordinating effective pacing. This innovation marks a significant advancement in heart health management.

In July 2022, Orchestra BioMed, a US-based company specializing in transformative therapeutic products, entered into a collaboration with Medtronic. The partnership between Medtronic and Orchestra BioMed aims to develop BackBeat Cardiac Neuromodulation Therapy (CNT), a potential therapeutic solution for hypertension in individuals requiring a cardiac pacemaker. This collaboration underscores the commitment of major players, such as Medtronic, to pioneer advancements in healthcare technology and contribute to the evolution of cardiac care.

Major companies operating in the cardiac pacemakers market include Medtronic plc, Lepu Medical Technology Co., Abbott Inc., Biotronik SE & Co. KG, Boston Scientific Corporation, Oscor Inc., Osypca Medical GmbH, Zoll Medical Corporation, MicroPort Scientific Corporation, Cook Group Incorporated, Sorin Group, Vitatron & Medical Co., Cordis Inc., Shree Pacetronix Limited, Medico SpA, St. Jude Medical, LivaNova PLC, Schiller AG, BTL Industries Inc., CCC Medical Devices, Cardiostim, Advena Ltd., Mediana Co. Ltd., Vimecon GmbH, Cardiac Science Corporation, Greatbatch Medical, Galix Biomedical Instrumentation, Nanjing MicroPort Medical, Cardionovum GmbH.

The cardiac pacemaker is defined by small electronic devices that generate electrical impulses to regulate heartbeats and treat conditions like arrhythmias. These devices play a crucial role in preventing the heart from beating too fast or too slow.

The primary categories of cardiac pacemakers consist of implantable and external variants. Implantable cardiac pacemakers, installed through surgery, are electronic devices generating electrical impulses within the chest to maintain a regular heart rate. Different technologies in cardiac pacemakers encompass biventricular, single-chambered, and dual-chambered systems. These devices find applications in treating various conditions such as arrhythmias, heart blockage, atrial fibrillation, long QT syndrome, and congestive cardiac failure. Cardiac pacemakers serve end-users including clinics, hospitals, ambulatory surgical centers, and cardiac care centers. The market continues to evolve with ongoing advancements in technology and surgical procedures, contributing to improved patient care and outcomes.

The cardiac pacemakers market research report is one of a series of new reports that provides cardiac pacemakers market statistics, including cardiac pacemakers industry global market size, regional shares, competitors with a cardiac pacemakers market share, detailed cardiac pacemakers market segments, market trends and opportunities, and any further data you may need to thrive in the cardiac pacemakers industry. This cardiac pacemakers market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

North America was the largest region in the cardiac pacemakers market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cardiac pacemakers market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

The countries covered in the cardiac pacemakers market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK and USA.

The cardiac pacemaker market consists of sales of single chamber, dual chamber and Biventricular pacemakers. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.